Dry eye is a chronic syndrome and is a progressive depending upon the cause and severity. It is a condition when a person does not have tears to lubricate his or her eyes. Tears are an essential part of maintaining good health of the eye and assist in providing good vision. The syndrome is commonly seen among older people and is becoming common among people spending a long time in front of the computer. The factors that can cause dry eye include age, medications, environmental conditions, long term use of contact lenses. The conditions cannot be cured completely; however, it can be managed by using medical products.
ALLERGAN(Abbvie) and ALCON (NOVARTIS) – Notable Market Players in Middle East and Africa Dry Eye Products Market
Market leaders operating in the market have undertaken various organic growth strategies in the Middle East and Africa dry eye products market. The North America market majorly consists of the players Novartis AG, Santen Pharmaceuticals Co. Ltd, Johnson and Johnson Services Incare among others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the companies have utilized inorganic strategies including mergers & acquisitions, partnership, and collaborations.
Below is the list of the growth strategies done by the players operating in the Middle East and Africa dry eye products market:
| Year | News |
| Jan-2020 | Santen Pharmaceutical Co., Ltd as a part of its business expansion in China has decided to construct its second plant for its Chinese subsidiary “Santen Pharmaceutical (China) Co., Ltd.” to support the growing demand for products in China. |
| May-2019 | Novartis acquired worldwide assets associated with Xiidra (is a lifitegrast ophthalmic solution) 5% from Takeda Pharmaceutical Company Limited. This acquisition has helped the company in expanding its eye care portfolio and growing influence in the eye care market. Xiidra is a prescription drug that is the only FDA-approved for dry eye treatment explicitly indicated for the symptoms of dry eye. |
| Feb-2017 | Johnson & Johnson acquired Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The acquisition was made for an all-cash of $4.325 billion. Originally this transaction was announced Sept. 16, 2016. The purchase provided the company expansion of its Johnson & Johnson Vision (J&J Vision) products and brand portfolio in relation to ophthalmic care; the products included cataract surgery, laser refractive surgery, and consumer eye health. |
| Nov-2017 | Santen Pharmaceutical Co., Ltd received its import drug license for its product Diquas Ophthalmic Solution (generic name: diquafosol sodium), for the dry eye treatment of patients in China. This approval has provided the company high potential for business growth in the region and country |
